Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline
Methodological detailsGRADE methodology, systematic reviews, multidisciplinary panel, 8 clinical questions prioritized by a multidisciplinary panel; GRADE used to assess certainty of evidence
- GRADE methodology
- Systematic reviews
- Multidisciplinary panel
- 8 clinical questions prioritized by a multidisciplinary panel; GRADE used to assess certainty of evidence
Recommendations
As issued by the authors
- strong recommendation
In adults with hypercalcemia of malignancy (HCM), treatment with DMAB or an intravenous (IV) bisphosphonate (BP)
- conditional recommendation; low certainty of evidence
In adults with HCM, DMAB rather than an IV BP
- conditional recommendation; low certainty of evidence
In adults with severe HCM, calcitonin plus an IV BP or DMAB as initial treatment
- conditional recommendation; low certainty of evidence
In adults with refractory/recurrent HCM despite BP treatment, DMAB
- conditional recommendation; low certainty of evidence
Add an IV BP or DMAB in adults with hypercalcemia due to tumors with high calcitriol levels already on glucocorticoids but with persistent severe or symptomatic HCM
- conditional recommendation; low certainty of evidence
In adults with hypercalcemia due to parathyroid carcinoma, either a calcimimetic or an antiresorptive (IV BP or DMAB)
Original publication
Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. Published 21 December 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →